Navigation Links
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Date:11/1/2008

lt in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during treatment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and men must use two forms of effective contraception during treatment and during the 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. If pregnancy should occur during treatment or during 6 months post-therapy, the patient must be advised of the significant teratogenic risk of COPEGUS therapy to the fetus. Healthcare providers and patients are strongly encouraged to immediately report any pregnancy in a patient or partner of a patient during treatment or during 6 months after treatment cessation to the Ribavirin Pregnancy Registry at 1-800-593-2214. '/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
2. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
5. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
6. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Decision Resources, one of the world,s leading research ... finds that the cost of Roche/Chugai,s Avastin, followed ... are cited most frequently by surveyed oncologists as ... non-small-cell lung cancer treatment in Germany, France, Italy, ... Special European Physician & Payer Forum report entitled ...
(Date:12/17/2009)... ORLANDO, Fla., Dec. 17 MedX Limited, ... -branded medical exercise equipment and a subsidiary of ... the sale of 227 MedX exercise ... list of countries, including Australia, Germany, India, Scotland, ... sold MedX equipment will be used ...
(Date:12/17/2009)... Inc., (OTC Bulletin Board: SCIE) disclosed today that its ... letter to shareholders: ,, As the end of the ... the recent closing of a $4.3 million round of ... ramping our business performance as we head into 2010. ... force. We are increasing our sales and marketing activities ...
Breaking Medicine Technology:Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 2Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 3WellTek Subsidiary MedX Limited Increases Presence in Global Market 2WellTek Subsidiary MedX Limited Increases Presence in Global Market 3WellTek Subsidiary MedX Limited Increases Presence in Global Market 4SpectraScience Releases Shareholder Newsletter 2SpectraScience Releases Shareholder Newsletter 3SpectraScience Releases Shareholder Newsletter 4SpectraScience Releases Shareholder Newsletter 5Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 1Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 2Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 3Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 4Purple Communications Dream Bigger Initiative Honors Cancer Survivor and Deaf Community Activist as Trailblazer 5110 5Abbott Cuts Use of Oil and Coal by 35 Percent 5108 1Abbott Cuts Use of Oil and Coal by 35 Percent 5108 2Abbott Cuts Use of Oil and Coal by 35 Percent 5108 3Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 5106 1Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 5106 2
... American Association for Cancer Research,annual meeting -, ... Inc. today presented preclinical data demonstrating potent,anti- ... the,efficacy and safety in animal models of ... are both attractive targets,for an antibody-drug conjugate ...
... OncoGenex Technologies,Inc. announced today data from a Phase II ... with metastatic breast,cancer (MBC). Data was presented by the ... the American Association for,Cancer Research 2007 Annual Meeting in ... concluded:, - ...
Other Medicine Technology:Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 2Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 3Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 4OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 2OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 3OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 4
(Date:12/17/2009)... Dec. 17 Reportlinker.com announces that ... in its catalogue: ,, India Healthcare ... 2015 ,, http://www.reportlinker.com/p0169911/India-Healthcare-IT-Investment-Opportunities-Analysis-and-Forecasts-to-2015.html ,, ... Forecasts to 2015 ,, Summary ... for in-depth information and data relating to ...
(Date:12/17/2009)... YORK, Dec. 17 Reportlinker.com ... report is available in its catalogue: ... strategic assessment of the competitive environment ... the highest priority management responsibilities, the ... and profitability. Timely and factual competitive ...
(Date:12/17/2009)... 17 Today, CDC,s Morbidity and Mortality ... the number of state-level epidemiologists has decreased steadily ... 10% since 2006. There was also a substantial ... period, including epidemiology capacity for bioterrorism and emergency ... such as occupational health, substance abuse, and oral ...
(Date:12/17/2009)... Dec. 17 /PRNewswire-Asia/ -- China,s leading high-tech,healthcare group, ... Stock Code: 801) is pleased to announce today ... (FunTalk), formerly known as,Pypo China Holdings Limited, made ... ) after a successful secondary offering. The shares ... (Eastern Time). , As ...
(Date:12/17/2009)... HONG KONG, Dec. 17 /PRNewswire-Asia/ -- China,s leading ... or "the,Group"; Stock Code: 801) is pleased to ... During the period under review, the Group,s two,associate ... Stock Exchange and NASDAQ;,its key businesses have been ... new hospital management operations. , ...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 2Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 3Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 4Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 5Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 6Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 7Health News:Reportlinker Adds India Healthcare IT Investment Opportunities, Analysis and Forecasts to 2015 8Health News:Reportlinker Adds Top Ten World's Leading Life Science Intermediates Companies 2Health News:CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking 2Health News:Golden Meditech's Associate Company Debuted on NASDAQ 2Health News:Golden Meditech Announces Interim Results of FY2009/10 2Health News:Golden Meditech Announces Interim Results of FY2009/10 3
... June 23 ,Debiotech and STMicroelectronics (NYSE: ... a unique miniaturized insulin-delivery pump. The,tiny device ... patch to provide continuous,insulin infusion, enabling substantial ... quality of life of diabetes patients. The,breakthrough ...
... to support the Coordinating Office for Terrorism Preparedness and ... ... Martin (NYSE: LMT ) was,selected by the Centers for Disease ... Coordinating Office for,Terrorism Preparedness and Emergency Response (COTPER) in Atlanta. This,task ...
... chronic inflammatory rheumatic disease, associated with stiffening of the ... been diagnosed in Germany, but milder forms of the ... by Dr. Roland R. Wick, with Dr. Elke A. ... Prof. Dr. Wolfgang Gssner have conducted a long-term follow-up ...
... of early-stage tumors, researchers say, , , MONDAY, June 23 (HealthDay ... ovarian cancer detection by 20 percent through use of a ... a woman,s report of new-onset symptoms. , Using either ... cancers in a high-risk group of women, while the two ...
... to, Convenience Stores, Gas Stations, Bodegas, Independent Pharmacies ... Health Food Stores in the ... MedeFile,International, Inc. (OTC Bulletin Board: MDFI), a company specializing in,portable ... South Florida-based API Marketing, Sales & Advertising,Company the exclusive right ...
... 23 Medco Health,Solutions, Inc. (NYSE: MHS ... Health Care, Inc. (NYSE: CVH ), a ... Medco, the leading independent pharmacy benefits manager, ... all of Coventry,s Medicare,programs, covering approximately one million ...
Other Medicine News:Health News:STMicroelectronics and Debiotech Announce First Prototypes of Disposable Insulin Nanopump 2Health News:STMicroelectronics and Debiotech Announce First Prototypes of Disposable Insulin Nanopump 3Health News:Lockheed Martin Wins $24 Million IT Contract With CDC 2Health News:Increased cancer risk following the use of radioactive Radium-224 in the therapy 2Health News:Symptoms Plus Blood Test Boost Ovarian Cancer Detection 2Health News:Symptoms Plus Blood Test Boost Ovarian Cancer Detection 3Health News:MedeFile To Be Marketed in Over 100,000 Retail Outlets 2Health News:MedeFile To Be Marketed in Over 100,000 Retail Outlets 3Health News:MedeFile To Be Marketed in Over 100,000 Retail Outlets 4Health News:Coventry Health Care Awards Medicare Pharmacy Services Contract to Medco 2Health News:Coventry Health Care Awards Medicare Pharmacy Services Contract to Medco 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: